IHL

Incannex Healthcare

Short interest: 0.32%; −0.03 pp 30d; as of 29 Nov 2023
Reported shorts: 5M
Shares on issue: 1.587B

Incannex Healthcare (IHL) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine

Neutral

19 Aug

Incannex Healthcare (ASX:IHL) Cash Flow Check: What Investors Need to Watch on 19 August

Highlights BHP reported FY26 results on 18 August, with copper overtaking iron ore as its largest earnings contributor and the company highlighting strong cash generation. Incannex Healthcare (ASX:IHL) is the primary company lens, while ECS Botanics (ASX:ECS), Cann Group (ASX:CAN), Little Green Pharma (ASX:LGP) provide category context. The article focuses on regulatory execution, funding needs and commercial traction without using directional investment recommendations. The central question ...

Kalkine

Neutral

13 Aug

Incannex Healthcare (ASX:IHL) Clinical Development Pipeline: Market Outlook

Highlights Clinical trials progressing across multiple therapeutic indications Combination medicine approach addressing complex neurological conditions Regulatory pathway clarity supporting development timelines Incannex Healthcare (ASX:IHL) advances clinical development programs targeting chronic conditions where combination medicines address underlying biological pathways. The company executes clinical trials across sleep, neurological, and mental health indications. The broader market co...

Kalkine

Neutral

12 Aug

Why Are Incannex Healthcare (ASX:IHL), Cann Group (ASX:CAN), ECS Botanics (ASX:ECS) and Little Green Pharma (ASX:LGP) Back in the Market Spotlight?

Highlights Incannex Healthcare and Cann Group are being assessed through operational delivery, strategic priorities and the quality of their underlying platforms. ECS Botanics and Little Green Pharma highlight how sector conditions can create different requirements across established and emerging business models. Capital discipline, customer relevance and consistent execution remain central as the four companies progress their current work programs. Australias market conversation is being sha...

Kalkine

Neutral

6 July

Incannex Healthcare (ASX:IHL): Why Is This Cannabis Innovator Back in Focus?

Highlights Incannex Healthcare has secured a significant United States patent for its lead cannabinoid-based sleep apnoea therapy. Clinical development continues across both sleep disorder and psychedelic anxiety treatment programs. A strong debt-free balance sheet is supporting ongoing research and development activities. Incannex Healthcare strengthened its clinical development profile after securing a United States patent while advancing c...

Kalkine

Neutral

23 June

Why Is Incannex (ASX:IHL) Emerging as a Clinical Cannabis Story?

Highlights Incannex Healthcare is pursuing clinical-stage programs focused on cannabinoid and psychedelic-based therapies. The company is advancing regulatory pathways linked to pharmaceutical development rather than medicinal cannabis product sales. Clinical-stage cannabis companies continue to attract attention as evidence-driven healthcare innovation gains importance. Incannex Healthcare is pursuing cannabinoid and psychedelic-based clinical programs, highlighting the growing focus o...